{"keywords": [{"value": "Drugs (Pharmaceuticals)", "rank": "1", "is_major": "N", "name": "subject"}, {"value": "Valeant Pharmaceuticals International Inc", "rank": "2", "is_major": "N", "name": "organizations"}, {"value": "Food and Drug Administration", "rank": "3", "is_major": "N", "name": "organizations"}], "headline": {"kicker": "Letter", "print_headline": "Time to Import Drugs", "content_kicker": "Letter", "main": "Time to Import Drugs"}, "byline": [], "web_url": "http://www.nytimes.com/2015/10/10/opinion/time-to-import-drugs.html", "source": "The New York Times", "subsection_name": null, "slideshow_credits": null, "type_of_material": "Letter", "_id": "56184d9438f0d814e13703c5", "multimedia": [], "pub_date": "2015-10-10T00:00:00Z", "print_page": "20", "section_name": "Opinion", "word_count": "93", "blog": [], "news_desk": "Letters", "snippet": "A retired drug company executive faults the price tactics of certain companies.", "document_type": "article", "abstract": null, "lead_paragraph": "A retired drug company executive faults the price tactics of certain companies."}